Drug Trial Radar · NCT03351062
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
844
Planned (sponsor's estimate)
Start
Nov 2017
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Chinese Anti-Cancer AssociationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fudan University; Henan Cancer Hospital; The First Hospital of Jilin University; Southwest Hospital, China; First Hospital of China Medical University; Guangdong Provincial People's Hospital; Harbin Medical University; First Affiliated Hospital of Chongqing Medical University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Jiangsu Provincial People's Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Zhejiang Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital; Union hospital of Fujian Medical University; Hebei Tumor Hospital; Hunan Cancer Hospital; Affiliated Hospital of Qinghai University; Wuhan TongJi Hospital; Hainan People's Hospital; The Third Affiliated Hospital of Kunming Medical College.; The Third Affiliated Hospital of Nanchang University
- First posted
- Nov 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be compared in CYP2D6 intermediate/poor metabolizers of premenopausal patients with estrogen receptor-positive early breast cancer.
Conditions
- Breast Cancer Female
Interventions
TamoxifenDrug
Patients will be given 10mg Tamoxifen twice a day.
ToremifeneDrug
Patients will be given 60mg Toremifene once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free SurvivalTime frame: Within 5 years after randomization
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Southwest Hospital, China
Chongqing, Chongqing Municipality, China · Recruiting
Union hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China · Recruiting
Hainan People's Hospital
Haikou, Hainan, China · Recruiting
Hebei Tumor Hospital
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Wuhan Tongji Hospital
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
The Third Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
First Hospital of China Medical University
Shenyang, Lining, China · Recruiting
First Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The Third Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.